JOHN L HIGGINS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN L HIGGINS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN L HIGGINS. JOHN L HIGGINS is an Chief Executive Officer in LIGAND PHARMACEUTICALS INC ($LGND) and a in BIO-TECHNE Corp ($TECH) and a Director in BIO-TECHNE Corp ($TECH) and a EVP, Finance, Corp Dev. & CFO in CONNETICS CORP ($CNCT).
Address: 3290 W. BAYSHORE ROAD PALO ALTO 94303 CA
Companies in which JOHN L HIGGINS is an Insider
BIO-TECHNE Corp
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of JOHN L HIGGINS:
Holdings: 9,412 shares
Current Value: $952,306
Latest Transaction: Nov 10 2020
$TECH Market Capitalization: $3.73B
$TECH Previous Close: $101.18
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
CONNETICS CORP
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN L HIGGINS: EVP, Finance, Corp Dev. & CFO
Holdings: 81,195 shares
Current Value: $0
Latest Transaction: Mar 16 2004
$CNCT Market Capitalization: $389378.34
$CNCT Previous Close: $0.00
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
LIGAND PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN L HIGGINS: Chief Executive Officer
Holdings: 340,696 shares
Current Value: $36,740,657
Latest Transaction: Feb 09 2021
$LGND Market Capitalization: $2.24B
$LGND Previous Close: $107.84
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of JOHN L HIGGINS
Sentiment: All, TECH, CNCT, LGND
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 54,666 | 791,017 | 14,334 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 10.05 | 60,000 | 603,000 | 0 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 203.03 | 2,970 | 602,999 | 343,060 | 346 K to 343.1 K (-0.86 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 10.05 | 60,000 | 603,000 | 346,030 | 286 K to 346 K (+20.98 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 203.40 | 54,666 | 11,119,239 | 286,030 | 340.7 K to 286 K (-16.05 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 54,666 | 791,017 | 340,696 | 286 K to 340.7 K (+19.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 177.50 | 25,113 | 4,457,558 | 25,113 |